This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New Strong Sell Stocks for March 29th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Sarepta (SRPT) Reports Positive Interim Results for DMD Drug
by Zacks Equity Research
Sarepta???s (SRPT) key pipeline candidate leads to statistically significant increase in dystrophin production in ESSENCE study. NDA to be filed mid-2019.
New Strong Sell Stocks for March 27th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Why Is BioMarin (BMRN) Down 0.9% Since Last Earnings Report?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for March 18th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for March 7th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Sarepta (SRPT) Q4 Earnings Lag Estimates, Exondys 51 Sales Up
by Zacks Equity Research
Sarepta (SRPT) misses estimates for both earnings and sales in fourth-quarter 2018. However, Exondys 51 performs well on strong demand.
BioMarin (BMRN) Q4 Earnings & Sales Miss, Shares Decline
by Zacks Equity Research
BioMarin (BMRN) misses estimates for earnings and revenues in the fourth quarter. Shares decline in after-hours trading.
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
by Kinjel Shah
Here are five stocks that are attractive and most likely to be takeout targets in 2019.
Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger
by Zacks Equity Research
Shire's (SHPG) pending acquisition by Takeda Pharmaceuticals for $62 billion gets approval from shareholders of both the companies.
Sarepta Stock More Than Doubles This Year So Far: Here's Why
by Zacks Equity Research
Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is also making good progress. The company is also developing gene therapies.
BioMarin (BMRN) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
BioMarin's (BMRN) Q3 scores on earnings and revenue beat with a surge in demand for its key products.
Sarepta (SRPT) Q3 Earnings & Sales Miss, Exondys 51 Sales Up
by Zacks Equity Research
Sarepta (SRPT) misses estimates on both counts in third-quarter 2018. However, Exondys 51 performs well on strong demand.
BioMarin Pharmaceutical (BMRN) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on a single product for near-term growth is a concern.
BioMarin Pharmaceutical (BMRN) Catches Eye: Stock Jumps 7.9%
by Zacks Equity Research
BioMarin Pharmaceutical (BMRN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
BioMarin (BMRN) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
BioMarin (BMRN) reports mixed second-quarter results with earnings missing estimates but sales beating the same.
BioMarin Pharmaceutical (BMRN) Q2 Earnings Miss Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of -29.41% and 3.14%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Drug Stock Q2 Earnings Releases on Aug 2: ZTS, REGN & More
by Zacks Equity Research
Let's see how these pharma/biotech stocks are poised ahead of their scheduled results on Aug 2.
BioMarin (BMRN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
BioMarin (BMRN) is likely to see continued momentum in Kuvan and Vimizim sales in the second quarter. On the call, management is likely to comment on the launch preparation for pegvaliase.
Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III
by Zacks Equity Research
Pfizer (PFE) initiates phase III program on a gene therapy treatment, fidanacogene elaparvovec, for patients with hemophilia B.
Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on a single product for near-term growth is a concern.
BioMarin Pharmaceutical (BMRN) Catches Eye: Stock Jumps 8.5%
by Zacks Equity Research
BioMarin Pharmaceutical (BMRN) shares rose nearly 9% in the last trading session, amid huge volumes.
BioMarin Begins Pediatric Study on Achondroplasia Candidate
by Zacks Equity Research
BioMarin Pharmaceutical (BMRN) initiates phase II study on vosoritide for the treatment of achondroplasia in infants and children up to five years of age.